The Cardiovascular Drugs Market encompasses pharmaceutical agents used to treat disorders of the heart and blood vessels, collectively known as Cardiovascular Diseases (CVDs). This vital market includes several therapeutic classes, such as antihypertensives (ACE inhibitors, ARBs), antihyperlipidemics (statins, PCSK9 inhibitors), anticoagulants/antiplatelets (blood thinners), and drugs for heart failure and arrhythmia. (2026-2033)
Global Cardiovascular Drugs Market is forecasted for steady expansion. Revenue is projected to grow from approximately USD 185.69 billion in 2025 to an estimated USD 264.48 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of approximately four and a half percent across the forecast period. This growth highlights the sustained global need for managing chronic heart conditions.
Showing all 2 results
-
Cardiovascular Disease Treatment Market Size, Share, Trends, and Forecast (2025–2034): Industry Gr...
Price range: $3,499.00 through $5,499.00Select options This product has multiple variants. The options may be chosen on the product pageReport ID : | No. of Pages : | Base Year for Estimate :The global Cardiovascular Disease Treatment Market, which largely encompasses cardiovascular drugs, is projected to grow from approximately USD 155.96 billion in 2025 to around USD 214.72 billion by 2034, at a Compound Annual Growth Rate (CAGR) of 3.62% during the forecast period. -
Heart Failure Therapeutics Market Analysis by Drug Class (ARNIs, SGLT2 Inhibitors, Beta-Blockers, MR...
Price range: $3,499.00 through $5,499.00Select options This product has multiple variants. The options may be chosen on the product pageReport ID : | No. of Pages : | Base Year for Estimate :The Heart Failure Therapeutics Market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.2% from 2025 to 2034. The market value is estimated to be approximately USD 14.6 Billion in 2024, and is expected to reach approximately USD 15.6 Billion by 2025.